Welcome to our dedicated page for Liquidia Corporation news (Ticker: LQDA), a resource for investors and traders seeking the latest updates and insights on Liquidia Corporation stock.
Liquidia Corporation (LQDA) is a biopharmaceutical innovator leveraging its proprietary PRINT® Technology to develop precision therapies for pulmonary hypertension and rare cardiopulmonary conditions. This page aggregates official company announcements, providing stakeholders with timely updates on clinical advancements, regulatory milestones, and strategic initiatives.
Investors and researchers will find curated press releases detailing progress in Liquidia’s pipeline, including YUTREPIA™ inhalation powder development, FDA communications, and technology licensing agreements. Content spans clinical trial results, manufacturing updates, and partnership announcements with global pharmaceutical entities.
Key categories include treatment efficacy studies, regulatory filings, intellectual property developments, and operational expansions. All materials adhere to factual reporting standards, ensuring reliable insights into the company’s scientific and business trajectory.
Bookmark this page for streamlined access to Liquidia’s latest verified updates. Combine regular visits with professional financial counsel to inform your investment strategy.
Liquidia Corporation (NASDAQ: LQDA) announced the grant of inducement stock options for 10,000 shares to newly hired non-executive employees under its Inducement Plan. Each option, intended as part of the employment compensation, is exercisable at $6.39 per share, the closing price on the grant date of February 1, 2023. The options have a ten-year term and vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly thereafter. The Inducement Plan specifically allows for non-statutory stock options for individuals who are new hires or returning after a period of non-employment.
Liquidia Corporation (NASDAQ: LQDA) announced a Revenue Interest Financing Agreement with HealthCare Royalty (HCRx), securing up to $100 million to support the launch of YUTREPIA™ (treprostinil) inhalation powder and other business activities. Liquidia will receive an initial $32.5 million, with additional tranches contingent on conditions like patent litigation outcomes. The agreement is intended to extend Liquidia's cash runway through at least 2024, providing non-dilutive capital while maintaining financial flexibility.
Liquidia Corporation (NASDAQ: LQDA) announced a collaboration with Sandoz and Mainbridge Health Partners to develop a new subcutaneous infusion pump for Treprostinil Injection, a generic version of Remodulin. The Pump Agreement includes equal sharing of development costs and aims for FDA submission in 2023. Additionally, Liquidia and Sandoz extended their promotion agreement for Treprostinil Injection through 2032. This partnership emphasizes Liquidia's commitment to enhance treatment options for pulmonary arterial hypertension (PAH) patients.
Liquidia Corporation (NASDAQ: LQDA) reported its Q3 2022 financial results, maintaining revenue at $3.2 million year-over-year. The company is preparing to launch YUTREPIA™ for PAH and PH-ILD following legal victories against United Therapeutics. Liquidia's cash increased to $98.3 million, up from $57.5 million in December 2021. However, the net loss widened to $9.1 million compared to $7.3 million in Q3 2021, attributed to rising administrative expenses.
Anavasi Diagnostics, a medical technology firm, has elected three new board members: Bryan Crane, PhD, from Illumina, Arthur Kirsch from Liquidia Corp, and David Vied from Cyanotech Corporation. This expansion aims to leverage their extensive industry experience to enhance Anavasi's growth as it progresses through clinical trials and product development. Nelson Patterson, CEO, expressed optimism about the fresh perspectives these members will bring. Anavasi has secured $6 million in seed funding and is currently in a $20 million Series A fundraising round.
Liquidia Corporation (NASDAQ: LQDA) will release its third quarter 2022 financial results on November 8, 2022. A conference call and webcast will follow at 8:30 a.m. ET for discussion of the results and corporate updates. Interested parties can join the live call by dialing 1-800-715-9871 (domestic) or 1-646-307-1963 (international), entering conference code 7467713. Additionally, a webcast will be accessible on Liquidia’s website for 30 days.
Liquidia Corporation (NASDAQ: LQDA) announced that the Precedential Opinion Panel of the USPTO denied United Therapeutics' request to review the PTAB decision that invalidated claims of U.S. Patent No. 10,716,793. The PTAB had ruled the claims unpatentable based on prior art presented by Liquidia. The decision supports Liquidia's position as it seeks final approval for YUTREPIA, its inhalation powder for treating pulmonary arterial hypertension (PAH). CEO Roger Jeffs expressed confidence in the ongoing rehearing process, anticipating a favorable outcome by mid-2024.
Liquidia Corporation (LQDA) announced data presentations for YUTREPIA™ (treprostinil) inhalation powder at the CHEST 2022 Annual Meeting. The data includes findings on higher dose efficacy compared to lower doses and the product's robustness in misuse scenarios. YUTREPIA is designed to treat pulmonary arterial hypertension (PAH) and was granted a tentative FDA approval in November 2021. The presentations will be accessible on the company's website post-event.
Liquidia Corporation (NASDAQ: LQDA) reported a favorable District Court ruling regarding U.S. Patent No. 9,593,066 (‘066 Patent) but an unfavorable outcome for U.S. Patent No. 10,716,793 (‘793 Patent). The court found five of six asserted claims of the ‘066 patent invalid and ruled that the valid claim was not infringed. All claims of the '793 patent were previously invalidated by the PTAB, impacting the FDA approval pathway for YUTREPIA™ (treprostinil) inhalation powder. The company plans to appeal the decision and has scheduled a conference call for September 1, 2022.
Liquidia Corporation (NASDAQ: LQDA) announced the grant of inducement stock options totaling 7,000 shares to newly hired non-executive employees under the 2022 Inducement Plan. Each option is priced at $7.44 per share, the closing price on August 19, 2022. The options have a vesting schedule of four years, with 25% vesting on the first anniversary and the remainder vesting monthly. This grant aligns with Nasdaq Listing Rule 5635(c)(4) to attract new talent. Liquidia focuses on developing products for pulmonary hypertension and other applications of its PRINT® Technology.
FAQ
What is the current stock price of Liquidia Corporation (LQDA)?
What is the market cap of Liquidia Corporation (LQDA)?
